Neuroacanthocytosis: Presenting With Depression
"Mr. A," a 38-year-old divorcee, presented to the department of neurology with complaints of alteration of the gait for the past 14 years. Since the age of 24, he had walked with a peculiar gait characterized by exaggerated lurching interspersed with sudden flexion movements at the hip and the knee joints bilaterally. He also had three episodes of generalized tonic clonic seizures when he was 26 years old; since then, he has been stabilized on 300 mg of phenytoin. For the past 3 years he has experienced difficulty with his speech and has found it difficult to articulate words. He also has experienced difficulty degluting solids. Following the onset of the illness, Mr. A lost his job, wife, and 6-year-old daughter. Neuroacanthocytosis is a progressive neurological disease first described by Levine in 1960 and characterized by movement disorders, personality changes, cognitive deterioration, axonal neuropathy, and seizures. Acanthocytes (Ͼ3%) are seen in peripheral blood smears. Neurochemical studies have revealed altered levels of catecholamines in various brain regions. Dopamine has been found to be decreased in almost the entire brain, and norepinephrine levels elevated in the putamen and globus pallidus. Studies have also reported decreased serotonin levels in the caudate nucleus and substantia nigra. The mean age of presentation ranges from 8 to 62 years with a possible male preponderance. Sporadic cases, as well as autosomal recessive, autosomal dominant, and X-linked inheritance patterns, have been reported. This disorder is linked to chromosome 9q21. Imaging studies have revealed caudate atrophy and increased signal in caudate and lentiform nuclei and hypometabolism in the neostriatum and the frontal cerebral cortical areas. The psychiatric manifestations of the disorder reported include personality changes, impulsivity, distractibility, anxiety, depression, apathy, loss of introspection, and compulsivity.
1,2 The treatment basically aims at supportive therapy and the management of associated behavioral symptoms.
Yatan Eight weeks after discharge she presented with 1 week of an inability to stand upright, being bent to the right, a mild degree of pain in the thoracic area, and significant emotional distress. Examination showed dystonic scoliosis of the thoracic spine with convexity to the left. No other muscle group was involved. There was no rigidity or involuntary movement in other parts of the body. She had a mild degree of akathisia. She had a history of normal birth and no associated medical problems. Aripiprazole was stopped while continuing all other medications. Within a week, akathisia subsided and in a month there was substantial improvement in dystonic symptoms. Three months later she remained free of dystonic symptoms.
The above clinical presentation satisfies the diagnostic criteria for tardive dystonia by Burke et al. 4 This case reminds us that despite its name, tardive dystonia is characterized more by the chronic nature of the dystonia than by the duration of antipsychotic exposure and is known to occur weeks or even days after use of antipsychotics. 4 Medications that could be implicated in tardive dystonia in this patient are ziprasidone, aripiprazole, venlafaxine, and trazodone. A drug-interaction software did not reveal any drug interaction relevant to this case. Trazodone 
Myasthenia Gravis Disclosed by Lithium Carbonate
SIR: A patient given lithium for bipolar disorder developed severe fatigue syndrome involving only the proximal limb muscles. The clinical and laboratory assessments revealed myasthenia gravis and thymic hyperplasia. Lithium was withdrawn and the patient underwent a thymectomy. A few months later the patient's symptoms followed a more classical myasthenic symptomatology pattern involving ocular and pharyngeal muscles. This change of the clinical manifestations may suggest that lithium modified the onset and pattern of myasthenic symptomatology. Treatment with lithium may produce muscle weakness as a transient side effect, early in the course of therapy. A severe neuromuscular junction disorder during lithium treatment has been reported in five cases. [1] [2] [3] [4] Lithium caused a myasthenic syndrome in four of them, which remitted fully after lithium withdrawal. [1] [2] [3] [4] One case of myasthenia gravis was unmasked by lithium and followed the typical course of the disease after lithium discontinuation. 4 We report here a similar case.
